Results 31 to 40 of about 67,507 (290)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]

, 2017
The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects.
De Felice, Francesca, Marampon, Francesco, Marchetti, Claudia, Musella, Angela, Tombolini, Vincenzo   +4 more
core   +2 more sources

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

Cell Reports, 2018
Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments.
João D. Barros-Silva, Douglas E. Linn, Ivana Steiner, Guoji Guo, Adnan Ali, Hubert Pakula, Garry Ashton, Isabel Peset, Michael Brown, Noel W. Clarke, Roderick T. Bronson, Guo-Cheng Yuan, Stuart H. Orkin, Zhe Li, Esther Baena   +14 more
doaj   +1 more source

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. [PDF]

, 2017
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications.
Alva, Ajjai S, Brockman, Scott, Chinnaiyan, Arul M, Chugh, Rashmi, Feng, Felix Y, Grasso, Catherine S, Gursky, Amy, Haakenson, Christine, Henderson, James, Herman, Kirk, Hovelson, Daniel H, Husain, Hatim, Hussain, Maha H, Kamberov, Emmanuel, Kandarpa, Malathi, Kang, Qing, Krauss, John C, Langmore, John, Liu, Chia-Jen, Lonigro, Robert J, Mills, Ryan E, Morgan, Todd M, Quist, Michael J, Ramnath, Nithya, Robinson, Dan, Smith, David C, Talpaz, Moshe, Tesmer, Tim, Tewari, Muneesh, Tomlins, Scott A, Tuck, Missy, Wang, Yugang   +31 more
core   +1 more source

Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. [PDF]

, 2017
PURPOSE/OBJECTIVES: Radium-223 is a first-in-class radiopharmaceutical recently approved for the treatment of castration-resistant prostate cancer in patients with symptomatic bone metastases.
Basch, Beer, Chen, Cookson, De Bono, Den, Dreicer, Fizazi, Hoskin, Kantoff, Keizman, Morris, Nilsson, Nilsson, Parker, Petrylak, Ryan, Scher, Siegel, Tannock, Tu   +20 more
core   +2 more sources

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. [PDF]

, 2019
BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant ...
Armstrong, Andrew J, Chang, Nancy N, Concepcion, Raoul S, Cooperberg, Matthew R, Harmon, Matt, Higano, Celestia S, Kantoff, Philip W, Kassabian, Vahan, McLeod, David G, Nordquist, Luke T, Penson, David F, Pieczonka, Christopher M, Quinn, David I, Sartor, A Oliver, Scholz, Mark C, Shore, Neal D, Tang, Hong, Tutrone, Ronald F, Tyler, Robert C, Vacirca, Jeffrey, Vogelzang, Nicholas J   +20 more
core   +2 more sources

Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer [PDF]

, 2018
Background: Obesity and aggressive prostate cancer (PC) may be linked, but how local peri-prostatic fat relates to tumour response following androgen deprivation therapy (ADT) is unknown.
Ahmad, Imran, Hendry, Jane, Leung, Hing Y., Nixon, Colin, Patel, Amit, Salji, Mark   +5 more
core   +1 more source

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Reports, 2022
Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya   +8 more
doaj   +1 more source

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. [PDF]

, 2016
The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined.
Borowsky, Alexander D, Cai, Demin, Chen, Hong-Wu, Duan, Zhijian, Evans, Christopher P, Evans, Ronald M, Gao, Allen C, Kung, Hsing-Jien, Lam, Kit S, Louie, Maggie C, Wang, Junjian, Xiang, Qiuping, Xu, Jianzhen, Xu, Yong, Xue, Xiaoqian, Yang, Joy C, Zhang, Yan, Zou, June X   +17 more
core   +2 more sources

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Pharmaceutics, 2022
Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is approved for the treatment of non-
Dhruvitkumar S. Sutaria, Grozdana Rasuo, Adam Harris, Ryan Johnson, Dale Miles, Jorge Daniel Gallo, Rucha Sane   +6 more
doaj   +1 more source